Online Only Articles

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma

Department of Biomolecular Medicine, Ghent University, Belgium;Cancer Research Institute Ghent (CRIG), Belgium
Department of Biomolecular Medicine, Ghent University, Belgium;Cancer Research Institute Ghent (CRIG), Belgium
Department of Biomolecular Medicine, Ghent University, Belgium;Cancer Research Institute Ghent (CRIG), Belgium
Department of Biomolecular Medicine, Ghent University, Belgium;Cancer Research Institute Ghent (CRIG), Belgium
Department of Biomolecular Medicine, Ghent University, Belgium;Cancer Research Institute Ghent (CRIG), Belgium;Diagnostic Sciences, Ghent University, Belgium
Department of Biomolecular Medicine, Ghent University, Belgium;Cancer Research Institute Ghent (CRIG), Belgium
Department of Biomolecular Medicine, Ghent University, Belgium;Cancer Research Institute Ghent (CRIG), Belgium
Department of Biomolecular Medicine, Ghent University, Belgium;Cancer Research Institute Ghent (CRIG), Belgium;Molecular and Cellular Oncology Lab, Department for Biomedical Molecular Biology, Ghent University, Belgium
Cancer Research Institute Ghent (CRIG), Belgium;Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Belgium
Department of Biomolecular Medicine, Ghent University, Belgium;Cancer Research Institute Ghent (CRIG), Belgium
Department of Hematology, APHP-Hôpital Necker, Paris, France
Department of Oncology, and Children’s Research Center, University Children’s Hospital Zurich, Switzerland
Department of Oncology, and Children’s Research Center, University Children’s Hospital Zurich, Switzerland
Department of Woman’s and Child’s Health, Hematology-Oncology Laboratory, Istituto di Ricerca Pediatrica (IRP) and University of Padova, Italy
Department of Woman’s and Child’s Health, Hematology-Oncology Laboratory, Istituto di Ricerca Pediatrica (IRP) and University of Padova, Italy
Department of Woman’s and Child’s Health, Hematology-Oncology Laboratory, Istituto di Ricerca Pediatrica (IRP) and University of Padova, Italy
Laboratory of Pharmaceutical Biotechnology, Ghent University, Belgium
Laboratory of Pharmaceutical Biotechnology, Ghent University, Belgium
Department of Pediatric Hematology-Oncology, University Hospitals Leuven, Belgium;Department of Oncology, KU Leuven, Belgium
Translational Cell and Tissue Research laboratory, KU Leuven, Belgium
Department of Pediatric Hematology and Oncology, University of Münster, Germany
Department of Pathology, Hematopathology Section, UKSH Campus Kiel, Germany
Cancer Research Institute Ghent (CRIG), Belgium;Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Belgium
Cancer Research Institute Ghent (CRIG), Belgium;Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Belgium
Department of Hematology, APHP-Hôpital Necker, Paris, France
Department of Oncology, and Children’s Research Center, University Children’s Hospital Zurich, Switzerland
Department of Woman’s and Child’s Health, Hematology-Oncology Laboratory, Istituto di Ricerca Pediatrica (IRP) and University of Padova, Italy
Department of Woman’s and Child’s Health, Hematology-Oncology Laboratory, Istituto di Ricerca Pediatrica (IRP) and University of Padova, Italy
Department of Oncology, and Children’s Research Center, University Children’s Hospital Zurich, Switzerland
The Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
Department of Hematology, University Hospitals Leuven, Belgium;Center for Human Genetics, KU Leuven, Belgium
Department of Biomolecular Medicine, Ghent University, Belgium;Cancer Research Institute Ghent (CRIG), Belgium
Vol. 104 No. 1 (2019): January, 2019 https://doi.org/10.3324/haematol.2018.199257